News Release

Printer Friendly Version View printer-friendly version
<< Back
DURECT to Present at the H.C. Wainwright Global Life Sciences Conference and Host an Upcoming KOL call on NASH

CUPERTINO, Calif., April 1, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Michael Arenberg, Chief Financial Officer, will be presenting at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9 at 10:50 a.m. BST / 05.50 a.m. EDT.  The conference is being held at the JW Marriott Grosvenor House in London.  Institutional investors and analysts that are attending the conference may request a one-on-one meeting through the conference coordinators.

A live audio webcast of the presentation will be available by accessing http://wsw.com/webcast/hcw4/drrx.

The live audio webcast of the presentation will also be available by accessing DURECT's homepage at www.durect.com and clicking on the "Investors" tab.  If you are unable to participate during the live webcast, the call will be archived on DURECT's website in the Event Calendar of the "Investors" section.

Key Opinion Leader (KOL) Call: Updated Logistics

On Wednesday, April 17, 2019 at 11:00am EDT/8:00am PDT, DURECT will be hosting a key opinion leader (KOL) call providing an overview of nonalcoholic steatohepatitis (NASH) and its progression, current treatment options and new treatments in development. The call will feature a presentation by KOL Brent Tetri, MD, Professor of Internal Medicine at Saint Louis University.  DURECT will also provide an overview of the Company's development program for DUR-928 and Dr. Tetri will be available to answer questions after the presentations.

Updated Dial-In & Webcast Information  

Wednesday, April 17 @ 11:00 am Eastern Time / 8:00 am Pacific Time

Domestic:

888-394-8218           

International:

323-794-2588

Conference ID:

1264564

Webcast w/Slides:

http://public.viavid.com/index.php?id=133834.

About DURECT Corporation

DURECT is a biopharmaceutical company actively developing therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms.  DUR‑928, a new chemical entity in Phase 2 development, is the lead candidate in DURECT's Epigenetic Regulator Program.  An endogenous, orally bioavailable small molecule, DUR-928 has been shown in preclinical studies to play an important regulatory role in lipid homeostasis, inflammation, and cell survival.  Human applications may include acute organ injury such as Alcoholic Hepatitis (AH) and acute kidney injury (AKI), hepatic diseases such as nonalcoholic steatohepatitis (NASH), and inflammatory skin conditions such as psoriasis and atopic dermatitis.  DURECT's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs.  Late stage product candidates in this category include POSIMIR® (bupivacaine extended-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to 3 days of continuous pain relief after surgery, and ORADUR®-Methylphenidate ER Capsules, approved in Taiwan as Methydur Sustained Release Capsules, where it is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).  In addition, for the assignment of certain patent rights, DURECT receives single digit sales-based earn-out payments from U.S. net sales of Indivior's PERSERIS (risperidone) drug for schizophrenia, which was approved in July 2018 and commercially launched in February 2019.  For more information, please visit www.durect.com.

DURECT Forward-Looking Statement

The statements in this press release regarding the potential use of DUR-928 to treat chronic hepatic diseases such as NASH, acute organ injuries such as alcoholic hepatitis (AH) and acute kidney injury (AKI), and in inflammatory skin disorders such as psoriasis and atopic dermatitis, the use of POSIMIR to treat post-surgical pain, the use of Indivior's PERSERIS to treat schizophrenia, as well as the potential commercial sales of Indivior's PERSERIS are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the risk of delays in the enrollment of the ongoing clinical trials of DUR-928 in NASH, AH and mild to moderate plaque psoriasis, potential adverse effects arising from the testing or use of DUR-928, the risk that the FDA may not approve the POSIMIR NDA, the risk that PERSERIS will not have a successful launch, our ability to avoid infringing patents held by other parties and secure and defend patents of our own patents, and our ability to manage and obtain capital to fund our operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-K on March 8, 2019 under the heading "Risk Factors."

NOTE: ORADUR®, POSIMIR® and SABER® are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. DUR-928, ORADUR-Methylphenidate ER Capsules and POSIMIR are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities. For PERSERIS full prescribing information visit www.perseris.com.

Cision View original content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-hc-wainwright-global-life-sciences-conference-and-host-an-upcoming-kol-call-on-nash-300821468.html

SOURCE DURECT Corporation

Mike Arenberg, Chief Financial Officer, DURECT, 408-346-1052